Mathias F. Heikenwalder
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 330 publications
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.
Journal: Science translational medicine
Published: June 03, 2026
Cancer prevention through metabolic remission.
Journal: Nature reviews. Endocrinology
Published: June 02, 2026
EASL position paper on preclinical models of steatotic liver disease.
Journal: Journal of hepatology
Published: April 28, 2026
MiR-122 regulates liver tolerance.
Journal: JHEP reports : innovation in hepatology
Published: March 18, 2026
12-HETE: a novel lipid mediator of CD8+ T cell dysfunction in MASH/HCC.
Journal: Gut
Published: March 10, 2026
Author Correction: Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation.
Journal: Nature immunology
Published: March 06, 2026
The versatile interplay between steatotic liver disease and liver cancer.
Journal: Nature reviews. Cancer
Published: February 24, 2026
Haemodynamic control of zonated liver function via instructive vascular Wnt signalling.
Journal: Nature communications
Published: February 03, 2026
Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS.
Journal: Cancer cell
Published: February 01, 2026
Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Journal: Nature medicine
Published: January 29, 2026
Current therapeutic landscape and future treatment perspectives of MASH.
Journal: Nature
Published: January 11, 2026
Last Updated: 09/26/2026